NCT04347915View on ClinicalTrials.gov

The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

February 24, 2021

Study Completion Date

February 26, 2021

Conditions
COVID-19
Interventions
DRUG

Clevudine

Clevudine 120mg once a day for 14 days (up to 21 days)

DRUG

Placebo

Matching Placebo once a day for 14 days (up to 21 days)

Trial Locations (1)

Unknown

Korea University Guro Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Bukwang Pharmaceutical

INDUSTRY

NCT04347915 - The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19 | Biotech Hunter | Biotech Hunter